Cantor Fitzgerald Reaffirms Neutral Rating for Replimune Group (NASDAQ:REPL)

Key Points

• Cantor Fitzgerald reiterated a "neutral" rating on Replimune, but multiple analysts sharply cut price targets (Wedbush, Leerink, Jefferies, BMO) and MarketBeat shows a consensus rating of "Reduce" with a $4.63 average price target.
• The FDA issued a Complete Response Letter (CRL) for Replimune’s RP1 BLA for advanced melanoma, a material regulatory setback that has generated negative headlines and legal/investigative attention.
• REPL shares are trading near recent lows (opened $1.58), with a market cap of about $130 million, high institutional ownership (~92.5%), and a recent insider sale executed under a Rule 10b5‑1 plan.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued on Monday,Benzinga reports.

Several other analysts also recently commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Replimune Group in a report on Monday, December 29th. Wedbush restated a "neutral" rating and set a $2.00 price target (down from $19.00) on shares of Replimune Group in a research report on Monday. JPMorgan Chase & Co. restated an "underweight" rating on shares of Replimune Group in a research report on Monday. BMO Capital Markets lowered shares of Replimune Group from a "market perform" rating to an "underperform" rating and set a $1.00 price target for the company. in a research report on Monday. Finally, Leerink Partners restated a "market perform" rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday. Six analysts have rated the stock with a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus price target of $4.63.

Replimune Group Price Performance

REPL stock opened at $1.58 on Monday. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a 12 month low of $1.53 and a 12 month high of $13.24. The firm has a market cap of $130.21 million, a P/E ratio of -0.46 and a beta of 0.74. The company's 50-day moving average price is $7.51 and its two-hundred day moving average price is $7.95.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.08. On average, analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the transaction, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company's stock.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently modified their holdings of the company. Invesco Ltd. boosted its position in shares of Replimune Group by 297.3% in the fourth quarter. Invesco Ltd. now owns 613,015 shares of the company's stock valued at $5,959,000 after acquiring an additional 458,714 shares during the period. XTX Topco Ltd bought a new position in shares of Replimune Group in the fourth quarter valued at approximately $322,000. Virtus Investment Advisers LLC boosted its position in shares of Replimune Group by 127.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,133 shares of the company's stock valued at $254,000 after acquiring an additional 14,622 shares during the period. SummitTX Capital L.P. bought a new position in shares of Replimune Group in the fourth quarter valued at approximately $1,058,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in shares of Replimune Group in the fourth quarter valued at approximately $650,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group News Summary

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Piper Sandler cut Replimune to Neutral, signaling less conviction on upside but not an outright sell rating; this reduces potential analyst-driven buying. Read More.
• Negative Sentiment: Jefferies reaffirmed a "hold" but slashed its price target from $13.00 to $2.00 — a large reduction that implies a steep downside vs. current levels and increases selling pressure. Read More.
• Negative Sentiment: Wedbush kept a neutral rating but cut its target from $19.00 to $2.00, another dramatic downward revision that signals low near-term valuation expectations. Read More. Read More.
• Negative Sentiment: JPMorgan reaffirmed an "underweight" rating, which is a continued negative tilt from a large institutional analyst. Read More.
• Negative Sentiment: HC Wainwright reaffirmed a "sell" rating, maintaining an explicit sell-side negative stance that can pressure flows and retail sentiment. Read More.
• Negative Sentiment: The FDA issued a complete response letter for Replimune’s RP1 Biologics License Application for advanced melanoma — a material regulatory setback that delays approval, revenue prospects and raises development/unlocking risk. Read More.
• Negative Sentiment: Mainstream coverage reports the FDA rejection and confirms the CRL, reinforcing negative headlines and investor concern about the program's pathway. Read More.
• Negative Sentiment: Following the FDA response, a securities law firm announced an investigation citing a large share-price drop, which can amplify legal risk perceptions and investor uncertainty. Read More.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.